Provided herein are various embodiments relating to antibodies and fusion proteins and uses thereof. Some of the embodiments include antibodies that bind CCR8. Some of the embodiments include fusion proteins that bind CCR8. Such antibodies and fusion proteins can be used in methods to treat, for example, cancer.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
A61K 39/00 - Medicinal preparations containing antigens or antibodies
The present disclosure relates generally to combinations of compounds of Formula: (I) or Formula: (II) with a P-glycoprotein inhibitor. Also disclosed are pharmaceutical compositions comprising said combinations. The combinations of the disclosure are useful in treating or preventing human immunodeficiency virus (HIV) infection.
C07D 498/22 - Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings
C07F 9/6561 - Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
A61K 31/496 - Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
Provided herein are compounds, and pharmaceutically acceptable salts thereof, useful as KRAS inhibitors, methods of making and using the same (singly or in combination with additional agents), and pharmaceutical compositions thereof.
C07D 519/00 - Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups or
A61K 31/553 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and at least one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
36 - Financial, insurance and real estate services
Goods & Services
Public policy consultancy in the field of healthcare and medicine related to HIV, hepatitis and oncology; promoting public awareness of screening and linkage to care for antiviral, hepatitis and oncology related diseases and disorders Providing grants for screening and linkage to care related to HIV, hepatitis and oncology
36 - Financial, insurance and real estate services
Goods & Services
Public policy consultancy in the field of healthcare and medicine related to HIV, hepatitis and oncology; promoting public awareness of screening and linkage to care for antiviral, hepatitis and oncology related diseases and disorders Providing grants for screening and linkage to care related to HIV, hepatitis and oncology
C07D 409/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
C07D 401/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
C07D 403/04 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings directly linked by a ring-member-to-ring- member bond
C07D 403/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing three or more hetero rings
C07D 405/14 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
C07D 413/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
C07D 491/107 - Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
The present disclosure relates to pharmaceutical compositions (e.g., tablets) comprising an human immunodeficiency virus (HIV) capsid inhibitor and a nucleoside reverse transcriptase translocation inhibitor (NRTTI), useful for the treatment of an HIV infection in a patient.
A61K 31/4439 - Non-condensed pyridinesHydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
A61K 31/7076 - Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
The application relates to KRAS G12D and/or KRAS G12C inhibitors of the general Formula (I) useful for the treatment of cancer (singly or in combination with additional agents), and pharmaceutical compositions comprising them.
C07D 471/22 - Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups in which the condensed systems contains four or more hetero rings
A61K 31/529 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim forming part of bridged ring systems
A61K 31/55 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceutical preparations for the treatment of viral infection, HIV infection and infectious diseases; Pharmaceutical preparations for the treatment and prevention of HIV and AIDS
44 - Medical, veterinary, hygienic and cosmetic services; agriculture, horticulture and forestry services
Goods & Services
Information and advisory services relating to pharmaceuticals, diseases and medical conditions and treatment, including such services provided on-line from a computer network or the Internet; providing information and advisory services regarding the diagnosis and treatment of diseases and medical disorders
The present disclosure relates to methods for treating or preventing pneumoviridae infections in a patient comprising administering compound 1 a pharmaceutically acceptable salt thereof, a deuterated compound thereof, or a pharmaceutically acceptable salt of a deuterated compound thereof.
A61K 31/706 - Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
A61K 31/706 - Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
05 - Pharmaceutical, veterinary and sanitary products
44 - Medical, veterinary, hygienic and cosmetic services; agriculture, horticulture and forestry services
Goods & Services
Pharmaceutical preparations. Information and advisory services relating to pharmaceuticals, diseases and medical conditions and treatment, including such services provided on-line from a computer network or the Internet; providing information and advisory services regarding the diagnosis and treatment of diseases and medical disorders.
05 - Pharmaceutical, veterinary and sanitary products
44 - Medical, veterinary, hygienic and cosmetic services; agriculture, horticulture and forestry services
Goods & Services
Pharmaceutical preparations. Information and advisory services relating to pharmaceuticals, diseases and medical conditions and treatment, including such services provided on-line from a computer network or the Internet; providing information and advisory services regarding the diagnosis and treatment of diseases and medical disorders.
Described herein are treatments and preventions for Head and Neck Squamous Cell Carcinoma (HNSCC) using the combination of zimberelimab and domvanalimab, in addition to one or more chemotherapeutic agents.
A61K 31/337 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
A61K 31/4745 - QuinolinesIsoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenanthrolines
A61K 31/475 - QuinolinesIsoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
A61K 31/7068 - Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
(1) Pharmaceutical preparations, namely antiviral and anti-inflammatory pharmaceutical preparations; pharmaceutical preparations for the treatment of infectious conditions; pharmaceutical preparations for the treatment of HIV infection; pharmaceutical preparations for the treatment of liver diseases and disorders; pharmaceutical preparations for the treatment of oncology diseases and disorders; pharmaceutical preparations for treatment of metabolic conditions; pharmaceutical preparations for treatment of obesity; pharmaceutical preparations for endocrine diseases and disorders; pharmaceutical preparations for treatment of metabolic conditions; pharmaceutical preparations for treatment of obesity; pharmaceutical preparations for endocrine diseases and disorders.
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
(1) Pharmaceutical preparations, namely antiviral and anti-inflammatory pharmaceutical preparations; pharmaceutical preparations for the treatment of infectious conditions; pharmaceutical preparations for the treatment of HIV infection; pharmaceutical preparations for the treatment of liver diseases and disorders; pharmaceutical preparations for the treatment of oncology diseases and disorders; pharmaceutical preparations for treatment of metabolic conditions; pharmaceutical preparations for treatment of obesity; pharmaceutical preparations for endocrine diseases and disorders; pharmaceutical preparations for treatment of metabolic conditions; pharmaceutical preparations for treatment of obesity; pharmaceutical preparations for endocrine diseases and disorders.
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
(1) Pharmaceutical preparations, namely antiviral and anti-inflammatory pharmaceutical preparations; pharmaceutical preparations for the treatment of infectious conditions; pharmaceutical preparations for the treatment of HIV infection; pharmaceutical preparations for the treatment of liver diseases and disorders; pharmaceutical preparations for the treatment of oncology diseases and disorders; pharmaceutical preparations for treatment of metabolic conditions; pharmaceutical preparations for treatment of obesity; pharmaceutical preparations for endocrine diseases and disorders; pharmaceutical preparations for treatment of metabolic conditions; pharmaceutical preparations for treatment of obesity; pharmaceutical preparations for endocrine diseases and disorders.
05 - Pharmaceutical, veterinary and sanitary products
44 - Medical, veterinary, hygienic and cosmetic services; agriculture, horticulture and forestry services
Goods & Services
Pharmaceutical preparations. Information and advisory services relating to pharmaceuticals, diseases and medical conditions and treatment, including such services provided on-line from a computer network or the Internet; providing information and advisory services regarding the diagnosis and treatment of diseases and medical disorders.
05 - Pharmaceutical, veterinary and sanitary products
44 - Medical, veterinary, hygienic and cosmetic services; agriculture, horticulture and forestry services
Goods & Services
Pharmaceutical preparations. Information and advisory services relating to pharmaceuticals, diseases and medical conditions and treatment, including such services provided on-line from a computer network or the Internet; providing information and advisory services regarding the diagnosis and treatment of diseases and medical disorders.
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceutical preparations for the treatment and prevention of HIV infection; Pharmaceutical preparations for the treatment of viral infection, fungal infection, fibrosis, liver diseases and disorders, hepatitis, hematological diseases and disorders, oncological diseases and disorders, inflammatory diseases and disorders, autoimmune diseases and disorders, respiratory and pulmonary diseases and disorders, kidney and nephrotic diseases and disorders, arthritis, obesity, metabolic diseases and disorders, endocrine diseases and disorders, and gastrointestinal diseases and disorders
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceutical preparations for the treatment and prevention of HIV infection; Pharmaceutical preparations for the treatment of viral infection, fungal infection, fibrosis, liver diseases and disorders, hepatitis, hematological diseases and disorders, oncological diseases and disorders, inflammatory diseases and disorders, autoimmune diseases and disorders, respiratory and pulmonary diseases and disorders, kidney and nephrotic diseases and disorders, arthritis, obesity, metabolic diseases and disorders, endocrine diseases and disorders, and gastrointestinal diseases and disorders
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceutical preparations for the treatment and prevention of HIV infection; Pharmaceutical preparations for the treatment of viral infection, fungal infection, fibrosis, liver diseases and disorders, hepatitis, hematological diseases and disorders, oncological diseases and disorders, inflammatory diseases and disorders, autoimmune diseases and disorders, respiratory and pulmonary diseases and disorders, kidney and nephrotic diseases and disorders, arthritis, obesity, metabolic diseases and disorders, endocrine diseases and disorders, and gastrointestinal diseases and disorders
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceutical preparations for the treatment and prevention of HIV infection; Pharmaceutical preparations for the treatment of viral infection, fungal infection, fibrosis, liver diseases and disorders, hepatitis, hematological diseases and disorders, oncological diseases and disorders, inflammatory diseases and disorders, autoimmune diseases and disorders, respiratory and pulmonary diseases and disorders, kidney and nephrotic diseases and disorders, arthritis, obesity, metabolic diseases and disorders, endocrine diseases and disorders, and gastrointestinal diseases and disorders
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceutical preparations for the treatment and prevention of HIV infection; Pharmaceutical preparations for the treatment of viral infection, fungal infection, fibrosis, liver diseases and disorders, hepatitis, hematological diseases and disorders, oncological diseases and disorders, inflammatory diseases and disorders, autoimmune diseases and disorders, respiratory and pulmonary diseases and disorders, kidney and nephrotic diseases and disorders, arthritis, obesity, metabolic diseases and disorders, endocrine diseases and disorders, and gastrointestinal diseases and disorders
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
(1) Pharmaceutical preparations, namely antiviral and anti-inflammatory pharmaceutical preparations; pharmaceutical preparations for the treatment of infectious conditions; pharmaceutical preparations for the treatment of HIV infection; pharmaceutical preparations for the treatment of liver diseases and disorders; pharmaceutical preparations for the treatment of oncology diseases and disorders; pharmaceutical preparations for treatment of metabolic conditions; pharmaceutical preparations for treatment of obesity; pharmaceutical preparations for endocrine diseases and disorders; pharmaceutical preparations for treatment of metabolic conditions; pharmaceutical preparations for treatment of obesity; pharmaceutical preparations for endocrine diseases and disorders.
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceutical preparations for the treatment and prevention of HIV infection; Pharmaceutical preparations for the treatment of viral infection, fungal infection, fibrosis, liver diseases and disorders, hepatitis, hematological diseases and disorders, oncological diseases and disorders, inflammatory diseases and disorders, autoimmune diseases and disorders, respiratory and pulmonary diseases and disorders, kidney and nephrotic diseases and disorders, arthritis, obesity, metabolic diseases and disorders, endocrine diseases and disorders, and gastrointestinal diseases and disorders
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceutical preparations for the treatment and prevention of HIV infection; Pharmaceutical preparations for the treatment of viral infection, fungal infection, fibrosis, liver diseases and disorders, hepatitis, hematological diseases and disorders, oncological diseases and disorders, inflammatory diseases and disorders, autoimmune diseases and disorders, respiratory and pulmonary diseases and disorders, kidney and nephrotic diseases and disorders, arthritis, obesity, metabolic diseases and disorders, endocrine diseases and disorders, and gastrointestinal diseases and disorders
The present disclosure relates to methods for determining the magnitude of a subject's immune response against a HIVACAT T-cell immunogen (HTI or “HTI immunogen”) and whether the subject can avoid antiretroviral therapy (ART). These methods are helpful for treating human immunodeficiency virus (HIV) and/or deciding whether to administer, continue or stop antiretroviral therapy in a subject. The present disclosure also relates to antigens, compositions, and kits related to such methods.
The disclosure provides a solid oral dosage form comprising bictegravir or a pharmaceutically acceptable salt thereof, and lenacapavir or a pharmaceutically acceptable salt thereof.
A61K 31/4439 - Non-condensed pyridinesHydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
A61K 31/553 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and at least one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
e.g.e.g., tablets) comprising an human immunodeficiency virus (HIV) capsid inhibitor and a nucleoside reverse transcriptase translocation inhibitor (NRTTI), useful for the treatment of an HIV infection in a patient.
A61K 31/4439 - Non-condensed pyridinesHydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
A61K 31/7076 - Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceutical preparations for the treatment and prevention of HIV infection; Pharmaceutical preparations for the treatment of viral infection, fungal infection, fibrosis, liver diseases and disorders, hepatitis, hematological diseases and disorders, oncological diseases and disorders, inflammatory diseases and disorders, autoimmune diseases and disorders, respiratory and pulmonary diseases and disorders, kidney and nephrotic diseases and disorders, arthritis, obesity, metabolic diseases and disorders, endocrine diseases and disorders, and gastrointestinal diseases and disorders
Provided are HBV immunogenic polypeptides, polynucleotides encoding such polypeptides, vectors expressing such immunogenic polypeptides for use in eliciting an immune response against HBV; pharmaceutical and immunogenic compositions and kits comprising such polypeptides, polynucleotides or vectors, and methods of use in treating and/or preventing HBV.
C07D 267/16 - Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems condensed with two six-membered rings
C07C 311/13 - Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing rings the carbon skeleton containing six-membered aromatic rings
C07D 317/30 - Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
C07D 319/06 - 1,3-DioxanesHydrogenated 1,3-dioxanes not condensed with other rings
C07D 413/12 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
Provided herein are various embodiments relating to anti-CCR8 binding agents, that bind to CCR8, and uses thereof. Some of the embodiments include antibodies, fragments thereof, variants thereof, derivatives thereof, and binding polypeptides targeting the same that bind CCR8. Such anti-CCR8 binding agents can be used in methods to treat, for example, cancer.
G01N 33/68 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving proteins, peptides or amino acids
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
G01N 33/569 - ImmunoassayBiospecific binding assayMaterials therefor for microorganisms, e.g. protozoa, bacteria, viruses
G01N 33/574 - ImmunoassayBiospecific binding assayMaterials therefor for cancer
The present disclosure relates generally to compounds which bind to the NR1H4 receptor (FXR) and act as agonists of FXR. The disclosure further relates to the use of the compounds for the preparation of a medicament for the treatment of diseases and/or conditions through binding of said nuclear receptor by said compounds and to a process for the synthesis of said compounds.
C07D 413/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
C07D 401/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
(1) Pharmaceutical preparations for the treatment of liver diseases and disorders; pharmaceutical preparations for the treatment of hematological diseases and disorders; pharmaceutical preparations for the treatment of oncological diseases and disorders; pharmaceutical preparations for the treatment of respiratory and pulmonary diseases, disorders and infections; pharmaceutical preparations for the treatment of digestive diseases and disorders, namely, crohn's disease, irritable bowel syndrome; antiviral pharmaceutical preparations; antifungal pharmaceutical preparations; anti-inflammatory pharmaceutical preparations; pharmaceutical preparations for autoimmune diseases and immunologic deficiency syndromes; anti-fibrotic pharmaceutical preparations; pharmaceutical preparations for the treatment of hepatitis; pharmaceutical preparations for the treatment and prevention of HIV infection; pharmaceutical preparations for the treatment of arthritis; pharmaceutical preparations for the treatment of kidney diseases and disorders; pharmaceutical preparations for the treatment of herpes simplex virus infection; pharmaceutical preparations for treatment of metabolic conditions; pharmaceutical preparations for treatment of obesity; pharmaceutical preparations for endocrine diseases and disorders.
C07D 519/00 - Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups or
A61K 31/553 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and at least one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceutical preparations for the treatment of viral infection, fungal infection, HIV infection, fibrosis, liver diseases and disorders, hepatitis, hematological diseases and disorders, cancer, inflammatory diseases and disorders, autoimmune diseases and disorders, respiratory and pulmonary diseases and disorders, kidney and nephrotic diseases and disorders, arthritis, obesity, metabolic diseases and disorders and gastrointestinal diseases and disorders
Modulators of signal transducer and activator of transcription 6 (STAT6) are provided, including compounds of Formula J, I and Ia, pharmaceutical compositions thereof, and methods of treating an inflammatory condition or disease.
C07F 9/6561 - Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
A61K 31/675 - Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
C07F 9/6558 - Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
05 - Pharmaceutical, veterinary and sanitary products
44 - Medical, veterinary, hygienic and cosmetic services; agriculture, horticulture and forestry services
Goods & Services
Pharmaceutical preparations. Information and advisory services relating to pharmaceuticals, diseases and medical conditions and treatment, including such services provided on-line from a computer network or the Internet; providing information and advisory services regarding the diagnosis and treatment of diseases and medical disorders.
The present disclosure relates generally to certain compounds, pharmaceutical compositions comprising said compounds, and methods of making and using said compounds and pharmaceutical compositions. The compounds and compositions provided herein may be used for the treatment or prevention of a Retroviridae infection, including an HIV infection.
C07D 401/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
C07F 9/6558 - Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
Compounds and methods of using said compounds, singly or in combination with additional agents, and pharmaceutical compositions of said compounds for the treatment of viral infections are disclosed.
C07F 9/6561 - Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
59.
BRIDGED TRICYCLIC CARBAMOYLPYRIDONE COMPOUNDS AND USES THEREOF
Compounds for use in treating or preventing human immunodeficiency virus (HIV) infection are disclosed. The compounds have the following Formula (I):
Compounds for use in treating or preventing human immunodeficiency virus (HIV) infection are disclosed. The compounds have the following Formula (I):
Compounds for use in treating or preventing human immunodeficiency virus (HIV) infection are disclosed. The compounds have the following Formula (I):
including stereoisomers and pharmaceutically acceptable salts thereof. Methods associated with the preparation and use of the disclosed compounds, as well as pharmaceutical compositions comprising such compounds are also disclosed.
C07D 491/22 - Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups , , or in which the condensed system contains four or more hetero rings
A compound of Formula (I):
A compound of Formula (I):
A compound of Formula (I):
pharmaceutically acceptable salts thereof, deuterated analogs thereof, compositions thereof, and methods of treating disease using a compound thereof, wherein the variable substituents are disclosed herein.
42 - Scientific, technological and industrial services, research and design
44 - Medical, veterinary, hygienic and cosmetic services; agriculture, horticulture and forestry services
Goods & Services
Providing temporary use of online non-downloadable chatbot software for for providing medical information Providing medical information in the field of oncology, virology, cell therapy, hepatology, hematology and inflammation via interactive chatbot software
44 - Medical, veterinary, hygienic and cosmetic services; agriculture, horticulture and forestry services
Goods & Services
Medical services; Telemedicine services; Providing medical information via a website; Charitable services, namely, patient assistance program to provide drugs free of charge to low-income patients without prescription drug coverage; charitable services, namely, patient assistance programs to provide medicines at low or no cost to low income patients
63.
Therapeutic compositions for treatment of human immunodeficiency virus
A solid oral dosage form is provided, comprising a compound of Formula I or a pharmaceutically acceptable salt thereof, tenofovir alafenamide or a pharmaceutically acceptable salt thereof, and emtricitabine or a pharmaceutically acceptable salt thereof.
A61K 31/5365 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and at least one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with heterocyclic ring systems
A61K 9/00 - Medicinal preparations characterised by special physical form
A61K 31/513 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
A61K 31/537 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and at least one oxygen as the ring hetero atoms, e.g. 1,2-oxazines spiro-condensed or forming part of bridged ring systems
A61K 31/553 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and at least one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
A61K 31/675 - Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
Retail pharmacy services; Pharmaceutical services, namely, processing online and telephone prescription orders in retail and central fill pharmacies; Appointment scheduling services; Mail order pharmacy services
Modulators of signal transducer and activator of transcription 6 (STAT6) are provided, including compounds of Formula J, I and Ia, pharmaceutical compositions thereof, and methods of treating an inflammatory condition or disease.
C07F 9/6558 - Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
A61P 29/00 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agentsNon-steroidal antiinflammatory drugs [NSAID]
C07F 9/6561 - Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
68.
METHODS AND PHARMACEUTICAL FORMULATIONS FOR TREATING VIRAL INFECTIONS
The disclosure provides methods of treating and/or preventing HIV infections using a Compound 1, or a pharmaceutically acceptable salt thereof, and a Compound 2, or a pharmaceutically acceptable salt thereof. The disclosure further provides pharmaceutical formulations, particularly solid oral dosage forms comprising a Compound 1, or a pharmaceutically acceptable salt thereof, and a Compound 2, or a pharmaceutically acceptable salt thereof.
A61K 31/551 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogens as ring hetero atoms, e.g. clozapine, dilazep
A61K 31/675 - Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
Human immunoglobulin light chain transgene constructs are provided that encode at least two different rearranged light chain V-J regions arranged in such a manner that only one of the alternate light chains is expressed from the construct upon recombination in B cells. In some embodiments, the transgene comprises two, three or four different rearranged light chain V-J regions. Transgenic animals comprising the transgene are also provided. The light chain transgenes thus allow for expression of two, three or four alternate fixed light chains in the animals. Methods of using the transgenic animals are also provided.
Human immunoglobulin light chain transgene constructs are provided that encode at least two different rearranged light chain V-J regions arranged in such a manner that only one of the alternate light chains is expressed from the construct upon recombination in B cells. In some embodiments, the transgene comprises two, three or four different rearranged light chain V-J regions. Transgenic animals comprising the transgene are also provided. The light chain transgenes thus allow for expression of two, three or four alternate fixed light chains in the animals. Methods of using the transgenic animals are also provided.
The present disclosure relates to pharmaceutical compositions comprising an HIV capsid inhibitor and methods for the treatment or prevention of a human immunodeficiency virus (HIV) infection in a patient.
A61K 31/4439 - Non-condensed pyridinesHydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
The present disclosure relates to a compound according to formula (1):
The present disclosure relates to a compound according to formula (1):
and pharmaceutically acceptable salts, hydrates, or solvates thereof. The disclosure further relates to said compounds for use in therapy, to pharmaceutical compositions comprising said compounds, to methods of treating diseases, e.g. dermal diseases, with said compounds, and to the use of said compounds in the manufacture of medicaments.
A61K 31/4985 - Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
A61K 31/4545 - Non-condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
A61K 31/496 - Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
A61K 31/501 - PyridazinesHydrogenated pyridazines not condensed and containing further heterocyclic rings
A61K 31/5025 - PyridazinesHydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
A61K 31/506 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
A61K 31/513 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
C07D 519/00 - Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups or
73.
(R)-5-FLUORO-2-METHYL-1-((R)-5-(PYRIDIN-2-YL)-2,3-DIHYDRO-1 H-INDENE-2-CARBONYL)INDOLINE-6-SULFONAMIDE FOR TREATMENT OF VIRAL INFECTIONS UNRESPONSIVE TO TREATMENT WITH A FIRST ANTIVIRAL THERAPY
The present disclosure provides methods and pharmaceutical formulations for the treatment and prophylaxis of a viral infection unresponsive to treatment with one or more first antiviral therapy using an indolinyl compound.
A61K 31/4418 - Non-condensed pyridinesHydrogenated derivatives thereof having a carbocyclic ring directly attached to the heterocyclic ring, e.g. cyproheptadine
A61P 31/22 - Antivirals for DNA viruses for herpes viruses
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceutical preparations for the treatment of viral infection, fungal infection, HIV infection, fibrosis, liver diseases and disorders, hepatitis, hematological diseases and disorders, cancer, inflammatory diseases and disorders, autoimmune diseases and disorders, respiratory and pulmonary diseases and disorders, kidney and nephrotic diseases and disorders, arthritis, obesity, metabolic diseases and disorders and gastrointestinal diseases and disorders; Pharmaceutical preparations for the prevention of HIV infection; Pharmaceutical preparations for the treatment and prevention of HIV infection
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceutical preparations for the treatment of viral infection, fungal infection, HIV infection, fibrosis, liver diseases and disorders, hepatitis, hematological diseases and disorders, cancer, inflammatory diseases and disorders, autoimmune diseases and disorders, respiratory and pulmonary diseases and disorders, kidney and nephrotic diseases and disorders, arthritis, obesity, metabolic diseases and disorders and gastrointestinal diseases and disorders; Pharmaceutical preparations for the prevention of HIV infection; Pharmaceutical preparations for the treatment and prevention of HIV infection
05 - Pharmaceutical, veterinary and sanitary products
44 - Medical, veterinary, hygienic and cosmetic services; agriculture, horticulture and forestry services
Goods & Services
Pharmaceutical preparations. Information and advisory services relating to pharmaceuticals, diseases and medical conditions and treatment, including such services provided on-line from a computer network or the Internet; providing information and advisory services regarding the diagnosis and treatment of diseases and medical disorders.
05 - Pharmaceutical, veterinary and sanitary products
44 - Medical, veterinary, hygienic and cosmetic services; agriculture, horticulture and forestry services
Goods & Services
Pharmaceutical preparations. Information and advisory services relating to pharmaceuticals, diseases and medical conditions and treatment, including such services provided on-line from a computer network or the Internet; providing information and advisory services regarding the diagnosis and treatment of diseases and medical disorders.
78.
PHARMACEUTICAL COMPOSITIONS COMPRISING HIV INTEGRASE INHIBITORS
The present disclosure relates to pharmaceutical compositions (e.g., suspension formulations) including a compound of Formula I:
The present disclosure relates to pharmaceutical compositions (e.g., suspension formulations) including a compound of Formula I:
The present disclosure relates to pharmaceutical compositions (e.g., suspension formulations) including a compound of Formula I:
or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable liquid vehicle.
The present disclosure relates to pharmaceutical compositions (e.g., suspension formulations) including a compound of Formula I:
or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable liquid vehicle.
Also disclosed are methods of treating or preventing human immunodeficiency virus (HIV) in a human, including administering to the human a pharmaceutical composition disclosed herein.
A61K 31/55 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
A61K 9/00 - Medicinal preparations characterised by special physical form
A61K 47/26 - Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharidesDerivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
A61K 47/44 - Oils, fats or waxes according to two or more groups of Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
The present disclosure relates to pharmaceutical formulations comprising a HIV capsid inhibitor and methods for the treatment or prevention of a human immunodeficiency virus (HIV) infection in a patient.
Novel modulators of STAT6 having the general formula (I)
Novel modulators of STAT6 having the general formula (I)
or a pharmaceutically acceptable salt or stereoisomer thereof, and their use in therapy, and pharmaceutical compositions comprising said compounds.
C07D 519/00 - Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups or
A61K 31/444 - Non-condensed pyridinesHydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. amrinone
A61K 31/4545 - Non-condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
A61K 31/496 - Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
A61K 31/501 - PyridazinesHydrogenated pyridazines not condensed and containing further heterocyclic rings
A61K 31/513 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
C07B 59/00 - Introduction of isotopes of elements into organic compounds
Pharmaceutical formulations, particularly solid oral dosage forms (e.g., tablets) comprising (i) the compound of Formula I in an amount of about 40 wt % to about 70 wt %, (ii) a filler, (iii) a disintegrating agent, (iv) and a lubricant are disclosed, as are uses thereof.
A61K 31/706 - Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
The present disclosure relates to pharmaceutical compositions comprising an HIV capsid inhibitor and methods for the treatment or prevention of a human immunodeficiency virus (HIV) infection in a patient.
A61K 31/4439 - Non-condensed pyridinesHydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
The present disclosure relates generally to compounds that inhibit PRMT5. The disclosure further relates to the use of the compounds for the preparation of a medicament for the treatment of diseases and/or conditions through inhibiting PRMT5. The disclosure further relates to the use of the compounds for the treatment of a disease or condition associated with chromosome 9p21 deletion, MTAP null, or any other MTAP deficiency. The disclosure further relates to the use of the compounds for the treatment of cancers.
A61K 31/4985 - Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
A61K 31/506 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
A61K 31/519 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
A61K 31/5377 - 1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
A61K 31/538 - 1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
A61K 31/5383 - 1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
A61K 31/5386 - 1,4-Oxazines, e.g. morpholine spiro-condensed or forming part of bridged ring systems
A61K 31/55 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
C07D 519/00 - Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups or
Provided herein are various embodiments relating to anti-CCR8 binding agents, that bind to CCR8, and uses thereof. Some of the embodiments include antibodies, fragments thereof, variants thereof, derivatives thereof, and binding polypeptides targeting the same that bind CCR8. Such anti-CCR8 binding agents can be used in methods to treat, for example, cancer.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
G01N 33/574 - ImmunoassayBiospecific binding assayMaterials therefor for cancer
85.
IKAROS ZINC FINGER FAMILY DEGRADERS AND USES THEREOF
The present disclosure relates generally to compounds that bind to and act as degraders of an IKAROS Family Zinc Finger (IKZF) protein, such as IKZF2 (Helios) and/or IKZF4 (Eos). The disclosure further relates to the use of the compounds for the preparation of a medicament for the treatment of diseases and/or conditions through binding and degradation of an IKZF protein, such as IKZF2 and/or IKZF4, including cancer.
C07D 401/04 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring- member bond
86.
PHARMACEUTICAL COMPOSITIONS COMPRISING HIV INTEGRASE INHIBITORS
The present disclosure relates to pharmaceutical compositions (e.g., suspension formulations) including a compound of Formula I: or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable liquid vehicle. Also disclosed are methods of treating or preventing human immunodeficiency virus (HIV) in a human, including administering to the human a pharmaceutical composition disclosed herein.
The present disclosure relates generally to compounds that inhibit PRMT5. The disclosure further relates to the use of the compounds for the preparation of a medicament for the treatment of diseases and/or conditions through inhibiting PRMT5. The disclosure further relates to the use of the compounds for the treatment of a disease or condition associated with chromosome 9p21 deletion or MTAP null. The disclosure further relates to the use of the compounds for the treatment of cancers.
C07D 519/00 - Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups or
A61K 31/4355 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having oxygen as a ring hetero atom
A61K 31/437 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
A61K 31/4375 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring hetero atom, e.g. quinolizines, naphthyridines, berberine, vincamine
A61K 31/538 - 1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
A61K 31/5386 - 1,4-Oxazines, e.g. morpholine spiro-condensed or forming part of bridged ring systems
C07B 59/00 - Introduction of isotopes of elements into organic compounds
The present disclosure relates to methods of treating a HR+/HER2- breast cancer in a human subject, wherein the subject has received previously endocrine-based therapy and at least two additional systemic therapies, comprising administering a pharmaceutical composition comprising SG.
A61K 47/68 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
A61K 9/00 - Medicinal preparations characterised by special physical form
